FDA Approves Exdensur (depemokimab) for the Treatment of Severe Asthma with an Eosinophilic Phenotype

Dec 17, 2025 - 10:00
 0  3
Philadelphia, PA -- December 16 2025 GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment of severe asthma characterised by an...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0